Can Ozempic Help You Quit Smoking?

The biology is interesting and early results are real, but the direct evidence is still too thin to treat GLP-1s as established smoking-cessation drugs.

The short answer

Not yet, at least not in the way people usually mean it. Ozempic is not an established smoking-cessation medication. But there is enough biological plausibility and enough early evidence around nicotine craving to make the question worth taking seriously.

Why people are asking

Once people started reporting reduced pull toward alcohol, food, and other urges on GLP-1 drugs, nicotine naturally entered the conversation. The appeal of the question is obvious. Smoking remains deeply hard to quit, and fear of post-quit weight gain is one reason some people relapse. A medication that touched both reward pull and weight regain would be clinically interesting.

What the evidence actually shows

A recent randomized clinical trial in adults with daily cigarette use found that semaglutide significantly reduced weekly cigarette craving relative to placebo and improved weight and HbA1c, but it did not produce a clean, headline-ready reduction in cigarettes smoked per day across the main planned analyses. In plain English: the craving signal is meaningful, but the full “this helps people quit smoking” claim is still ahead of the evidence.

Why the field is moving cautiously

Much of the trial work now underway is built around post-quit weight gain, not smoking cessation as the main endpoint. That tells you something important. Researchers see a plausible role, but they are not yet treating GLP-1 drugs as proven cessation tools. Current standard smoking treatments like nicotine replacement, varenicline, and counseling still have the stronger evidence base.

Why this matters for Joy Gap

Joy Gap sits in the space where people notice changes before the literature fully catches up. If someone says cigarettes feel less compelling on a GLP-1, that belongs in the record. But community reports should not be inflated into treatment guidance. The honest position is that a real signal may be emerging, while direct quit-efficacy evidence remains thin.

What this means now

If a person wants to stop smoking, it makes more sense to use established cessation support than to wait for GLP-1 evidence to mature. At the same time, it is reasonable to study whether these medications reduce nicotine craving for some people. Both statements can be true without contradiction.